News & Insights

Welcome to our latest update on the outsourced Pharma Commercialisation Services sector. In this report we will be reviewing deal activity across 2022 and taking a look forward to see what 2023 may hold for the sector. We hope that you enjoy this report and look forward to discussing the data and underlying themes with […]

We are pleased to share our introduction to Pharma Licensing. This guide provides an overview of both in and out-licensing as well as insights on what to anticipate during the process. We hope that you find this guide useful and look forward to discussing the underlying themes with you. Do get in touch! Click to […]

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]

Welcome to our MedTech Services Report. This sets out our views on the tailwinds driving growth and increased outsourcing, an overview of the MedTech CDMO and CRO market as well as the key drivers of consolidation in the sector. We hope that you enjoy this report and look forward to discussing the data and underlying […]

Welcome to our latest update on the outsourced Pharma Commercialisation Services sector.  As well as our usual update on M&A activity, this report takes a deep dive into one of the biggest challenges businesses are currently facing – the War for Talent. A phrase first coined by McKinsey in the late ’90s but one that […]

We are very excited to share that we have agreed to join forces with Canaccord Genuity – a leading full-service investment bank serving growth companies in the middle market.  This is an important milestone in our journey and we wanted to update you on why we’ve taken this decision and what it means for you. […]

The healthcare industry experienced a revolutionary shift when it switched from practising medicine as an art to evidence-based medicine, which is based on relatively simple randomised clinical trials to determine which treatment option was safe and effective. Through the years, evidence-based medicine became the gold standard for clinical development. However, this method has become less […]

The biopharma universe gathered in San Diego last week for the first face to face BIO International conference in three years. Turn-out was good but below the get-together in Philadelphia in 2019. That one topped out above 17,000 attendees according to the BIO website; whisper numbers this time around were in the region of 12,000. I […]

Biotech funding is the key driver of innovation in the pharmaceutical industry and is essential in supporting the healthcare ecosystem. More than 80% of drugs marketed by large pharmaceutical companies were discovered and initially developed by biotechs1. Biotech companies also discovered more than 60% of FDA-approved “priority” drugs, which treat life-threatening conditions and offer significant […]